NCT06568562 - XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

XL092

XL092 will be supplied as a tablet that will be taken at home once a day. Participants should drink at least 8 ounces of water with each dose of XL092. Participants should not eat at least 2 hours before taking the dose and 1 hour after. Participants will be given enough XL092 to take at home for a full cycle.

Trial Locations (1)

84112

RECRUITING

Huntsman Cancer Institute at University of Utah, Salt Lake City